Literature DB >> 26396684

Identification of Bidentate Salicylic Acid Inhibitors of PTP1B.

Sina Haftchenary1, Andriana O Jouk1, Isabelle Aubry2, Andrew M Lewis1, Melissa Landry2, Daniel P Ball1, Andrew E Shouksmith1, Catherine V Collins1, Michel L Tremblay2, Patrick T Gunning1.   

Abstract

PTP1B is a master regulator in the insulin and leptin metabolic pathways. Hyper-activated PTP1B results in insulin resistance and is viewed as a key factor in the onset of type II diabetes and obesity. Moreover, inhibition of PTP1B expression in cancer cells dramatically inhibits cell growth in vitro and in vivo. Herein, we report the computationally guided optimization of a salicylic acid-based PTP1B inhibitor 6, identifying new and more potent bidentate PTP1B inhibitors, such as 20h, which exhibited a > 4-fold improvement in activity. In CHO-IR cells, 20f, 20h, and 20j suppressed PTP1B activity and restored insulin receptor phosphorylation levels. Notably, 20f, which displayed a 5-fold selectivity for PTP1B over the closely related PTPσ protein, showed no inhibition of PTP-LAR, PRL2 A/S, MKPX, or papain. Finally, 20i and 20j displayed nanomolar inhibition of PTPσ, representing interesting lead compounds for further investigation.

Entities:  

Keywords:  PTP1B; PTPσ; bidentate inhibitors; diabetes; insulin receptor; salicylic acid; small molecule inhibitor

Year:  2015        PMID: 26396684      PMCID: PMC4569880          DOI: 10.1021/acsmedchemlett.5b00171

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  35 in total

1.  Recent advances in the discovery of competitive protein tyrosine phosphatase 1B inhibitors for the treatment of diabetes, obesity, and cancer.

Authors:  Andrew P Combs
Journal:  J Med Chem       Date:  2010-03-25       Impact factor: 7.446

2.  Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy.

Authors:  Bruce G Szczepankiewicz; Gang Liu; Philip J Hajduk; Cele Abad-Zapatero; Zhonghua Pei; Zhili Xin; Thomas H Lubben; James M Trevillyan; Michael A Stashko; Stephen J Ballaron; Heng Liang; Flora Huang; Charles W Hutchins; Stephen W Fesik; Michael R Jirousek
Journal:  J Am Chem Soc       Date:  2003-04-09       Impact factor: 15.419

Review 3.  PTP1B: a double agent in metabolism and oncogenesis.

Authors:  Shu-Chin Yip; Sayanti Saha; Jonathan Chernoff
Journal:  Trends Biochem Sci       Date:  2010-04-08       Impact factor: 13.807

4.  Cellular inhibition of protein tyrosine phosphatase 1B by uncharged thioxothiazolidinone derivatives.

Authors:  Matthew Stuible; Liang Zhao; Isabelle Aubry; Dirk Schmidt-Arras; Frank-D Böhmer; Chao-Jun Li; Michel L Tremblay
Journal:  Chembiochem       Date:  2007-01-22       Impact factor: 3.164

5.  Mechanism of inhibition of protein-tyrosine phosphatases by vanadate and pervanadate.

Authors:  G Huyer; S Liu; J Kelly; J Moffat; P Payette; B Kennedy; G Tsaprailis; M J Gresser; C Ramachandran
Journal:  J Biol Chem       Date:  1997-01-10       Impact factor: 5.157

Review 6.  Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report.

Authors:  Sina Haftchenary; Miriam Avadisian; Patrick T Gunning
Journal:  Anticancer Drugs       Date:  2011-02       Impact factor: 2.248

7.  PTPsigma is a receptor for chondroitin sulfate proteoglycan, an inhibitor of neural regeneration.

Authors:  Yingjie Shen; Alan P Tenney; Sarah A Busch; Kevin P Horn; Fernando X Cuascut; Kai Liu; Zhigang He; Jerry Silver; John G Flanagan
Journal:  Science       Date:  2009-10-15       Impact factor: 47.728

8.  Receptor protein tyrosine phosphatase sigma inhibits axonal regeneration and the rate of axon extension.

Authors:  K M Thompson; N Uetani; C Manitt; M Elchebly; M L Tremblay; T E Kennedy
Journal:  Mol Cell Neurosci       Date:  2003-08       Impact factor: 4.314

9.  Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities.

Authors:  Steven Fletcher; Jagdeep Singh; Xiaolei Zhang; Peibin Yue; Brent D G Page; Sumaiya Sharmeen; Vijay M Shahani; Wei Zhao; Aaron D Schimmer; James Turkson; Patrick T Gunning
Journal:  Chembiochem       Date:  2009-08-17       Impact factor: 3.164

Review 10.  Protein tyrosine phosphatases and breast cancer.

Authors:  Gilles Freiss; Françoise Vignon
Journal:  Crit Rev Oncol Hematol       Date:  2004-10       Impact factor: 6.312

View more
  5 in total

Review 1.  Phosphotyrosine isosteres: past, present and future.

Authors:  Robert A Cerulli; Joshua A Kritzer
Journal:  Org Biomol Chem       Date:  2019-11-28       Impact factor: 3.876

2.  PTP1B promotes aggressiveness of breast cancer cells by regulating PTEN but not EMT.

Authors:  Xue Liu; Qian Chen; Xu-Gang Hu; Xian-Chao Zhang; Ti-Wei Fu; Qing Liu; Yan Liang; Xi-Long Zhao; Xia Zhang; Yi-Fang Ping; Xiu-Wu Bian
Journal:  Tumour Biol       Date:  2016-07-27

3.  Differential impact of cold and hot tea extracts on tyrosine phosphatases regulating insulin receptor activity: a focus on PTP1B and LMW-PTP.

Authors:  Massimo Genovese; Simone Luti; Elisa Pardella; Mirella Vivoli-Vega; Luigia Pazzagli; Matteo Parri; Anna Caselli; Paolo Cirri; Paolo Paoli
Journal:  Eur J Nutr       Date:  2022-01-23       Impact factor: 5.614

4.  Synthesis, anti-inflammatory, bactericidal activities and docking studies of novel 1,2,3-triazoles derived from ibuprofen using click chemistry.

Authors:  Kishore Kumar Angajala; Sunitha Vianala; Ramesh Macha; M Raghavender; Murali Krishna Thupurani; P J Pathi
Journal:  Springerplus       Date:  2016-04-11

Review 5.  Computational Methods in Cooperation with Experimental Approaches to Design Protein Tyrosine Phosphatase 1B Inhibitors in Type 2 Diabetes Drug Design: A Review of the Achievements of This Century.

Authors:  Mara Ibeth Campos-Almazán; Alicia Hernández-Campos; Rafael Castillo; Erick Sierra-Campos; Mónica Valdez-Solana; Claudia Avitia-Domínguez; Alfredo Téllez-Valencia
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.